We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for tarlatamab (Amgen Australia Pty Ltd)
Active ingredients
tarlatamab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
powder for reconstitution with sterile water to be infused intravenously
Indication
The treatment of small cell lung cancer (SCLC)
Therapeutic area
Oncology